Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05623501 · ClinicalTrials.gov registry record · Phase 1
Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease
A Phase 1 study, sponsored by University of Southern California.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05623501 is a Phase 1 study that has not yet begun recruiting, run by University of Southern California. The registered enrollment target is 12 participants.
The verdict
NCT05623501, a Phase 1 study, has not yet begun recruiting, sponsored by University of Southern California.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).
Interventions
- DRUG Dihydromyricetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-15 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05623501
The ClinicalTrials.gov registry entry for NCT05623501 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dihydromyricetin is the first listed.
NCT05623501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05623501 about?
NCT05623501 is a clinical study titled "Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease". The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).
What is the current status of trial NCT05623501?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-15. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05623501?
The interventions under investigation include: Dihydromyricetin (DRUG).
Who is sponsoring clinical trial NCT05623501?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.